SKB BIO-B (06990.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec13

Kolon Biotech's HER2-targeted ADC drug Bozutuximab Fails to Obtain Approval for Third-line HER2 Positive Breast Cancer

08:54

Dec8

Kolon Biologics and Crescent Enter into Mutually Beneficial PD-1/VEGF+ADC License Agreement

03:28

Dec4

CoLon Biotech and Crescent Biopharma Enter into Collaboration for Oncology Drug Development

11:48

Dec3

Bernstein Analyst Gives Buy Rating to Sichuan Kelun Pharmaceutical H-Share

17:37

Nov27

Colonn Biotech's Core Product Sacituzumab Govitecan Shows Positive Results in NSCLC Phase III Clinical Trial

02:44

Nov25

Morgan Stanley Upgrades Kaiwen Biotech's Rating and Price Target

03:12

Schedules & Filings

Schedules

Filings

Aug18

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 520.14 M, Net Income -79.45 M, EPS -0.3486

Mar24

Earning Release(CST)

FY2024 Q4 Earning Release (HKD) Revenue 292.69 M, Net Income -306.92 M, EPS -1.375

Aug19

Earning Release(CST)

FY2024 Q2 Earning Release (HKD) Revenue 742.92 M, Net Income 166.67 M, EPS 0.7572

View More

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change

View More